Remove Containment Remove Development Remove Drug Delivery Systems Remove Medicine
article thumbnail

Leading commercial dose (non-sterile) companies in contract marketing

Pharmaceutical Technology

The information contained within the download document is intended for pharmaceutical manufacturers, wholesalers, retailers and distributors, pharmaceutical executives, medical representatives, business development managers, retail salesmen, sales managers, pharmacy executives, and any other individual involved in pharmaceutical marketing.

Marketing 130
article thumbnail

Unlocking the potential of mucoadhesive drug delivery

Drug Discovery World

Ashley Rein , Global Market Manager for Topical Drug Delivery at Lubrizol Life Science Health (LLS Health), explains how by using mucoadhesive drug delivery, developers can bring novel drugs to market and maximise the efficacy of pre-existing APIs. . Consider drug delivery systems early on .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Prefilled Syringes: Delivering Convenience and Precision in Every Dose

Roots Analysis

They offer several advantages over traditional drug delivery systems ( such as vials and syringes ), including reduced chances of dosing errors, increased patient compliance and decreased risk of microbial contamination. Further, they are useful in clearing blockage and maintain proper delivery of fluids and medications.

article thumbnail

Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting

The Pharma Data

A Retrospective Analysis: Visual Field Progression and Visual Acuity following Administration of Brimonidine Drug Delivery System. Developing Methotrexate-induced Immune Tolerance in a Rabbit Model of Persistent Retinal Vascular Leak. Poster session: Ocular Blood Flow, Laser Therapy, and IOP Measurements. Monday, May 3.